UY30783A1 - Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona, procesos para su preparacion y su uso como agentes farmacéuticos - Google Patents
Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona, procesos para su preparacion y su uso como agentes farmacéuticosInfo
- Publication number
- UY30783A1 UY30783A1 UY30783A UY30783A UY30783A1 UY 30783 A1 UY30783 A1 UY 30783A1 UY 30783 A UY30783 A UY 30783A UY 30783 A UY30783 A UY 30783A UY 30783 A1 UY30783 A1 UY 30783A1
- Authority
- UY
- Uruguay
- Prior art keywords
- derivatives
- oxadiazol
- sulfonil
- fenil
- ona
- Prior art date
Links
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 108010015181 PPAR delta Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- BIGWXAGEQONZGD-UHFFFAOYSA-N 2h-oxadiazol-5-one Chemical class O=C1C=NNO1 BIGWXAGEQONZGD-UHFFFAOYSA-N 0.000 abstract 1
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 206010012305 Demyelination Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 108010016731 PPAR gamma Proteins 0.000 abstract 1
- 102000000536 PPAR gamma Human genes 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06025880A EP1932843A1 (en) | 2006-12-14 | 2006-12-14 | Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY30783A1 true UY30783A1 (es) | 2008-07-31 |
Family
ID=37998695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY30783A UY30783A1 (es) | 2006-12-14 | 2007-12-12 | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona, procesos para su preparacion y su uso como agentes farmacéuticos |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8173674B2 (xx) |
| EP (2) | EP1932843A1 (xx) |
| JP (1) | JP2010512352A (xx) |
| KR (1) | KR20090087922A (xx) |
| CN (1) | CN101558064A (xx) |
| AR (1) | AR064299A1 (xx) |
| AU (1) | AU2007331805A1 (xx) |
| BR (1) | BRPI0720416A2 (xx) |
| CA (1) | CA2672347A1 (xx) |
| CL (1) | CL2007003614A1 (xx) |
| CO (1) | CO6210729A2 (xx) |
| CR (1) | CR10778A (xx) |
| EC (1) | ECSP099409A (xx) |
| MA (1) | MA30981B1 (xx) |
| MX (1) | MX2009005535A (xx) |
| NO (1) | NO20092293L (xx) |
| PE (1) | PE20081404A1 (xx) |
| RU (1) | RU2009126745A (xx) |
| SV (1) | SV2009003293A (xx) |
| TN (1) | TN2009000242A1 (xx) |
| TW (1) | TW200843749A (xx) |
| UY (1) | UY30783A1 (xx) |
| WO (1) | WO2008071311A1 (xx) |
| ZA (1) | ZA200903160B (xx) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2288607B1 (en) * | 2008-06-09 | 2014-09-24 | Sanofi | Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| AU2009256982A1 (en) | 2008-06-09 | 2009-12-17 | Sanofi-Aventis | Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| PL3851107T3 (pl) * | 2012-05-25 | 2023-03-06 | Corcept Therapeutics Incorporated | Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem |
| EP3371177A1 (en) | 2015-11-02 | 2018-09-12 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| EP3165094A1 (en) | 2015-11-03 | 2017-05-10 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| EP3370525A1 (en) | 2015-11-04 | 2018-09-12 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| CR20180332A (es) | 2015-11-19 | 2018-10-18 | Basf Se | Oxadiazoles sustituidos para combatir hongos fitopatógenos |
| JP2018537457A (ja) | 2015-11-19 | 2018-12-20 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | 植物病原菌を駆除するための置換オキサジアゾール |
| CN108884062A (zh) | 2016-04-11 | 2018-11-23 | 巴斯夫欧洲公司 | 用于防治植物病原性真菌的取代噁二唑类 |
| EP3468959A1 (en) | 2016-06-09 | 2019-04-17 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| WO2017211650A1 (en) | 2016-06-09 | 2017-12-14 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| EP3555056A1 (en) | 2016-12-19 | 2019-10-23 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| EP3339297A1 (en) | 2016-12-20 | 2018-06-27 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| CN110520121B (zh) | 2017-03-31 | 2023-07-04 | 科赛普特治疗学股份有限公司 | 糖皮质激素受体调节剂治疗宫颈癌 |
| WO2018219797A1 (en) | 2017-06-02 | 2018-12-06 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| EP3642187A1 (en) | 2017-06-19 | 2020-04-29 | Basf Se | 2-[[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]aryloxy](thio)acetamides for combating phytopathogenic fungi |
| WO2019002158A1 (en) | 2017-06-30 | 2019-01-03 | Basf Se | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR THE CONTROL OF PHYTOPATHOGENIC FUNGI |
| US11076596B2 (en) | 2017-09-18 | 2021-08-03 | Basf Se | Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi |
| WO2019101511A1 (en) | 2017-11-23 | 2019-05-31 | Basf Se | Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| IL284061B2 (en) | 2018-12-19 | 2025-02-01 | Corcept Therapeutics Inc | A preparation containing a relaxant |
| PH12021552025A1 (en) | 2019-02-22 | 2022-08-22 | Corcept Therapeutics Inc | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
| WO2021201609A1 (ko) * | 2020-03-31 | 2021-10-07 | 주식회사 엘지화학 | 췌도 이식 보호용 조성물 |
| WO2022134033A1 (en) | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| CN119997939A (zh) | 2022-10-06 | 2025-05-13 | 科赛普特治疗公司 | 糖皮质激素受体调节剂的制剂 |
| WO2024092195A1 (en) | 2022-10-28 | 2024-05-02 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
| DE10222034A1 (de) * | 2002-05-17 | 2003-11-27 | Bayer Ag | Tetrahydroisochinolin-Derivate |
| DE10229777A1 (de) * | 2002-07-03 | 2004-01-29 | Bayer Ag | Indolin-Phenylsulfonamid-Derivate |
| US20070105959A1 (en) * | 2003-03-11 | 2007-05-10 | Shinya Kusuda | Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient |
| US20060258683A1 (en) | 2003-04-07 | 2006-11-16 | Liu Kevin | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
| DE10335449A1 (de) | 2003-08-02 | 2005-02-17 | Bayer Healthcare Ag | Bicyclische Indolinsulfonamid-Derivate |
| DE602004004631D1 (de) * | 2004-04-01 | 2007-03-22 | Sanofi Aventis Deutschland | Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika |
-
2006
- 2006-12-14 EP EP06025880A patent/EP1932843A1/en not_active Withdrawn
-
2007
- 2007-11-30 CN CNA2007800454445A patent/CN101558064A/zh active Pending
- 2007-11-30 KR KR1020097012309A patent/KR20090087922A/ko not_active Withdrawn
- 2007-11-30 WO PCT/EP2007/010390 patent/WO2008071311A1/en not_active Ceased
- 2007-11-30 JP JP2009540626A patent/JP2010512352A/ja not_active Abandoned
- 2007-11-30 CA CA002672347A patent/CA2672347A1/en not_active Abandoned
- 2007-11-30 RU RU2009126745/04A patent/RU2009126745A/ru not_active Application Discontinuation
- 2007-11-30 MX MX2009005535A patent/MX2009005535A/es not_active Application Discontinuation
- 2007-11-30 AU AU2007331805A patent/AU2007331805A1/en not_active Abandoned
- 2007-11-30 BR BRPI0720416-7A patent/BRPI0720416A2/pt not_active IP Right Cessation
- 2007-11-30 EP EP07846915.2A patent/EP2102198B1/en active Active
- 2007-12-12 TW TW096147333A patent/TW200843749A/zh unknown
- 2007-12-12 PE PE2007001772A patent/PE20081404A1/es not_active Application Discontinuation
- 2007-12-12 AR ARP070105563A patent/AR064299A1/es not_active Application Discontinuation
- 2007-12-12 UY UY30783A patent/UY30783A1/es not_active Application Discontinuation
- 2007-12-12 CL CL200703614A patent/CL2007003614A1/es unknown
-
2009
- 2009-05-07 CR CR10778A patent/CR10778A/es not_active Application Discontinuation
- 2009-05-07 ZA ZA200903160A patent/ZA200903160B/xx unknown
- 2009-06-05 CO CO09058528A patent/CO6210729A2/es not_active Application Discontinuation
- 2009-06-09 US US12/480,974 patent/US8173674B2/en not_active Expired - Fee Related
- 2009-06-10 MA MA31971A patent/MA30981B1/fr unknown
- 2009-06-10 SV SV2009003293A patent/SV2009003293A/es unknown
- 2009-06-12 EC EC2009009409A patent/ECSP099409A/es unknown
- 2009-06-12 TN TNP2009000242A patent/TN2009000242A1/fr unknown
- 2009-06-15 NO NO20092293A patent/NO20092293L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0720416A2 (pt) | 2013-12-31 |
| NO20092293L (no) | 2009-09-08 |
| PE20081404A1 (es) | 2008-11-04 |
| EP1932843A1 (en) | 2008-06-18 |
| US8173674B2 (en) | 2012-05-08 |
| CN101558064A (zh) | 2009-10-14 |
| AR064299A1 (es) | 2009-03-25 |
| JP2010512352A (ja) | 2010-04-22 |
| CR10778A (es) | 2009-06-24 |
| WO2008071311A1 (en) | 2008-06-19 |
| SV2009003293A (es) | 2009-10-27 |
| EP2102198B1 (en) | 2015-02-25 |
| MA30981B1 (fr) | 2009-12-01 |
| ZA200903160B (en) | 2010-10-27 |
| EP2102198A1 (en) | 2009-09-23 |
| CO6210729A2 (es) | 2010-10-20 |
| CL2007003614A1 (es) | 2008-06-20 |
| TW200843749A (en) | 2008-11-16 |
| TN2009000242A1 (en) | 2010-10-18 |
| ECSP099409A (es) | 2009-07-31 |
| KR20090087922A (ko) | 2009-08-18 |
| RU2009126745A (ru) | 2011-01-20 |
| AU2007331805A1 (en) | 2008-06-19 |
| US20090298871A1 (en) | 2009-12-03 |
| MX2009005535A (es) | 2009-06-05 |
| CA2672347A1 (en) | 2008-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY30783A1 (es) | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona, procesos para su preparacion y su uso como agentes farmacéuticos | |
| ECSP088322A (es) | Derivados de fenil-1,2,4-oxadiazolona, procesos para su preparación y su uso como compuestos farmacéuticos | |
| UY29830A1 (es) | Derivados de fenil-(1,2,4)-oxadiazol-5-ona con grupo fenilo, procedimientos para su preparación y su uso como productos farmacéuticos. | |
| UY31872A (es) | Sulfonamidas n-heterocíclicas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparación y su uso como sustancias farmacéuticas | |
| UY31873A (es) | Pirrolidin sulfonamidas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparación y su uso como sustancias farmacéuticas | |
| CL2007003000A1 (es) | Compuestos derivados de biaril eter urea; composicion farmaceutica que los contienen; y su uso para el tratamiento de enfermedades o afecciones asociadas a la actividad de amida hidrolasa de acidos grasos (faah). | |
| CL2011002255A1 (es) | Compuestos derivados de 2-acetamino-5-aril-(1,2,4-triazolona o imidazolona), antagonista del receptor v1a y v2; composicion farmaceutica que los comprende; procedimiento de preparacion; y su uso en el tratamiento de insuficiencia cardiaca, hiponatremia hipervolemica y euvolemica, ascitis, ademas, entre otras. | |
| ECSP12011961A (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de | |
| CO6300957A2 (es) | Derivados de imidazo -[1,2,b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met | |
| GT200900056A (es) | Benzoxazoles y oxazolopiridinas utiles como inhibidores de la quinasa janus | |
| EA201070169A1 (ru) | 2,3-дигидробензо[1,4]диоксин-2-илметиловые производные в качестве альфа2с антагонистов для применения в лечении заболеваний перифирической центральной нервной системы | |
| SV2007002007A (es) | Compuestos de quinolina sustituidos ref. pc 25932a | |
| CR10243A (es) | "bencimidazoles 2-sustituidos como modulares de receptor de androgeno selectivos" | |
| UY30835A1 (es) | 8-alquinilxantinas y derivados | |
| AR072041A1 (es) | Piridil-n-(1,3,4) -tiadiazol-2-il-benceno sulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos | |
| AR060786A1 (es) | Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina | |
| CL2008001820A1 (es) | Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer. | |
| ECSP066892A (es) | Derivados de oxadiazolona como agonistas de ppar delta | |
| UY31874A (es) | Sulfonamidas con grupo de cabeza de heterociclo y oxadiazolona, procesos para su preparación y su uso como sustancias farmacéuticas | |
| UY28210A1 (es) | Derivados de ácido acético sustituido con cicloalquilmetoxi, procedimientos para su preparacion y su uso como farmacos. | |
| ECSP088176A (es) | Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6 | |
| UY29832A1 (es) | Derivados de 2-aminotiazoles y 2-aminooxazoles, procesos para su preparación y su uso como compuestos farmacéuticos. | |
| UY29847A1 (es) | N-(1,3,4)-tiadiazol-2-il-bencensulfonamidas cíclicas, procesos para su preparación y su uso como productos farmacéuticos. | |
| UY29848A1 (es) | (1,3,4)-tiadiazol-2-il-amidas bicíclicas del ácido aril-sulfónico, procesos para su preparación y su uso como productos farmacéuticos | |
| GT200500214A (es) | Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa epsilon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20130225 |